The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co ... easing knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe ...

Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

The approval is the second indication for Zepbound, which was approved for weight loss ... the new FDA green light doesn’t expand the number of people who may be eligible for the drug, since ...